Actualizado 03/04/2009 13:41
- Comunicado -

Long-Term Tolerability and Safety Data of ABILIFY(R) in Combination Treatment for Patients With Bipolar I Disorder (y 2)

Contact: Carmel Hogan, Bristol-Myers Squibb Company, Mobile: +33-6-74-10-76-58, carmel.hogan@bms.com.Alison Ross, Otsuka Pharmaceutical Europe Ltd, Mobile: +44-(0)7768-337-128, aross@otsuka-europe.com

Contenido patrocinado